In summary, HAIC combined with PD-(L)1 inhibitors and targeted drugs appears to have a favorable anti-tumor activity in patients with advanced, treatment-naive infiltrative HCC, with manageable toxicities. Here, CD274 is linked to hepatocellular carcinoma.